TY - JOUR
T1 - HPV testing for cervical cancer screening in Mozambique
T2 - Challenges and recommendations
AU - de Oliveira, Cristina M.
AU - Salcedo, Mila M.P.
AU - Mariano, Arlete
AU - Mariano, Arlete
AU - Verdinho, Mario J.C.
AU - Julião, Reginaldo De Alice M.
AU - Kundrod, Kathryn
AU - Smith, Chelsey
AU - Carns, Jennifer
AU - Andrade, Viviane
AU - Baker, Ellen
AU - Phoolcharoen, Natacha
AU - Richards-Kortum, Rebecca R.
AU - Fregnani, José Humberto T.G.
AU - Schmeler, Kathleen M.
N1 - Funding Information:
The authors would like to thank Qiagen for providing the careHPV system for the study. This study was supported in part by the National Institutes of Health through MD Anderson’s Cancer Center Support Grant P30CA016672; The Anadarko Petroleum Corporation; The Prevent Cancer Foundation; The Dunaway Family Fund; The Joe Family Fund; and The Giles-O’Malley Foundation.
Publisher Copyright:
© 2022, International Society of Global Health. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Background Cervical cancer is the fourth most common cancer affecting women worldwide and is the leading cause of cancer and related deaths among women in Mozambique. The World Health Organization (WHO) recommends screening with human papillomavirus (HPV) testing, but it has not yet been implemented in many low- and middle-income countries (LMICs). We conducted a cervical cancer screening study in Mozambique using the careHPV test (QIAGEN, Germantown, MD, USA). This study aimed to describe our experience with HPV testing for cervical cancer screening in Maputo, Mozambique, including challenges and lessons learned. Methods We conducted a cervical cancer screening pilot demonstration project at the General Hospital of Mavalane in Maputo, Mozambique, from April 2018 to September 2019, using primary HPV testing with careHPV. We performed the direct observations and discussions with participating laboratory experts, technicians, nurses and physicians from Mozambique, Brazil and the United States. Results HPV testing was successfully implemented. The main challenges we experienced were inadequately equipped laboratory facilities, a lack of laboratory and clinical staff expertise, and difficulties procuring equipment, tests and laboratory supplies. These challenges were overcome by increasing the budget to better equip the laboratory, building relationships with procurement and importation specialists and training sessions for laboratory personnel and medical providers. Conclusions Our findings suggest that primary HPV testing is achievable in Mozambique. Several challenges were identified and are being addressed for a successful scale-up.
AB - Background Cervical cancer is the fourth most common cancer affecting women worldwide and is the leading cause of cancer and related deaths among women in Mozambique. The World Health Organization (WHO) recommends screening with human papillomavirus (HPV) testing, but it has not yet been implemented in many low- and middle-income countries (LMICs). We conducted a cervical cancer screening study in Mozambique using the careHPV test (QIAGEN, Germantown, MD, USA). This study aimed to describe our experience with HPV testing for cervical cancer screening in Maputo, Mozambique, including challenges and lessons learned. Methods We conducted a cervical cancer screening pilot demonstration project at the General Hospital of Mavalane in Maputo, Mozambique, from April 2018 to September 2019, using primary HPV testing with careHPV. We performed the direct observations and discussions with participating laboratory experts, technicians, nurses and physicians from Mozambique, Brazil and the United States. Results HPV testing was successfully implemented. The main challenges we experienced were inadequately equipped laboratory facilities, a lack of laboratory and clinical staff expertise, and difficulties procuring equipment, tests and laboratory supplies. These challenges were overcome by increasing the budget to better equip the laboratory, building relationships with procurement and importation specialists and training sessions for laboratory personnel and medical providers. Conclusions Our findings suggest that primary HPV testing is achievable in Mozambique. Several challenges were identified and are being addressed for a successful scale-up.
KW - Cervical cancer
KW - Hpv
KW - Screening
UR - http://www.scopus.com/inward/record.url?scp=85163721146&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85163721146&partnerID=8YFLogxK
U2 - 10.29392/001c.32432
DO - 10.29392/001c.32432
M3 - Article
AN - SCOPUS:85163721146
SN - 2399-1623
VL - 6
JO - Journal of Global Health Reports
JF - Journal of Global Health Reports
M1 - e2022007
ER -